Online inquiry

IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3089MR)

This product GTTS-WQ3089MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FASLG gene. The antibody can be applied in Glioblastoma multiforme (GBM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000639.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 356
UniProt ID Q53ZZ1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3089MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ572MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 62-71-3
GTTS-WQ6235MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CR57
GTTS-WQ8214MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA hLIV22
GTTS-WQ2750MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG162
GTTS-WQ16015MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ZW-25
GTTS-WQ10366MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY2062430
GTTS-WQ10654MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3819253
GTTS-WQ4721MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BOS161721
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW